Benign neoplasm: Lacrimal gland and duct

DOID EFO MESH SNOMED PheWeb

choriocarcinoma: An aggressive malignant tumor arising from trophoblastic cells. The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells. Approximately half of the cases develop from a complete hydatidiform mole. A minority of cases arise in the testis or the ovaries. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.

Endpoint definition

↥

FinnGen phenotype data

Filter registries Inpat., Oupat., Death

Hospital Discharge: ICD-10 D31.5&

Hospital discharge: ICD-9 2247

Cause of death: ICD-10 D31.5&

Cause of death: ICD-9 2247

Check pre-conditions None

Include endpoints None

Check conditions None

Apply sex-specific rule None

CD2_BENIGN_LACRIMAL

Extra metadata

Level in the ICD hierarchy 3

First used in FinnGen datafreeze DF2

Parent code in ICD-10 D31

Name in latin Neoplasma benignum glandulae lacrimalis

Similar endpoints

↥

List of similar endpoints to Benign neoplasm: Lacrimal gland and duct based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

	All	Female	Male
Number of individuals	22	16	6
Unadjusted prevalence (%)	0.01	0.01	0.01
Mean age at first event (years)	57.55	57.80	56.90

Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Correlations

↥

Index endpoint: CD2_BENIGN_LACRIMAL – Benign neoplasm: Lacrimal gland and duct
GWS hits:

Survival analyses between endpoints

↥

Plot

before Benign neoplasm: Lacrimal gland and duct
after Benign neoplasm: Lacrimal gland and duct

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Benign neoplasm: Lacrimal gland and duct

↥